Jazz Pharmaceuticals JAZZ reported first-quarter 2025 adjusted earnings of $1.68 per share, which significantly missed the Zacks Consensus Estimate of $4.51. This miss was largely due to higher operating...
Axsome Therapeutics AXSM incurred an adjusted loss of $1.22 per share in the first quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.26. The company had incurred a loss of $1.44...
Jazz Pharmaceuticals JAZZ is set to report first-quarter 2025 earnings on May 6, after market close. The Zacks Consensus Estimate for the quarter’s sales and earnings is pegged at $978.6 million and...
Jazz Pharmaceuticals JAZZ and Harmony Biosciences HRMY have emerged as notable players in the neuroscience space, especially in the sleep disorder segment.Jazz Pharmaceuticals markets multiple neuroscience...
While JAZZ Pharmaceuticals JAZZ may not be a typical cannabis stock, it is the only company to market an FDA-approved drug that contains a purified drug substance derived from marijuana.The company entered...
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Fate Therapeutics FATE recently announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational pipeline candidate FT819 for the treatment of active...